Double Bond Pharmaceutical joins hands with SMS-oncology for clinical development of SI-053

Booking.com

Uppsala, Sweden and Schiphol, the Netherlands (09 Oct 2019) – Double Bond Pharmaceutical AS (“DBP”) announces today that Specialized Medical Services-oncology BV (“SMS-oncology”) has been chosen for providing consultancy services to support the transition of their lead candidate, SI-053 from the preclinical phase to the clinical phase.

DBP’s strategy is to develop new medicines, thereby combining already known efficient approaches with their innovative first-in-class technologies to provide new therapeutic possibilities for treatment of life-threatening diseases. Its lead compound SI-053

Booking.com

Source: Double Bond Pharmaceutical joins hands with SMS-oncology for clinical development of SI-053

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.